Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856297 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 389
- Enrollment target
NCT00856297 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 389 participants.
The verdict
NCT00856297, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 389 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescents previously enrolled in the V59P13 study who received either Novartis MenACWY Conjugate Vaccine or commercially available MenACWY conjugate vaccine. The study will also enroll age-matched subjects who have never received any other meningococcal vaccine (naïve subjects) to serve as an additional control group.
Interventions
- BIOLOGICAL MenACWY-CRM conjugate vaccine
- BIOLOGICAL Licensed comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856297
The ClinicalTrials.gov registry entry for NCT00856297 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MenACWY-CRM conjugate vaccine is the first listed.
NCT00856297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856297 about?
NCT00856297 is a clinical study titled "Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine". The primary objective is to evaluate the persistence of bactericidal antibodies in adolescents previously enrolled in the V59P13 study who received either Novartis MenACWY Conjugate Vaccine or commercially available MenACWY conjugate vaccine. The study will also enroll age-matched subjects who have ...
What is the current status of trial NCT00856297?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 389 participants. The study started on 2009-02. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00856297?
The interventions under investigation include: MenACWY-CRM conjugate vaccine (BIOLOGICAL), Licensed comparator (BIOLOGICAL).
Who is sponsoring clinical trial NCT00856297?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.